Sanofi Stock Xetra

Equities

SNW

FR0000120578

Pharmaceuticals

Market Closed - Xetra 11:35:43 2024-05-03 EDT 5-day change 1st Jan Change
91.56 EUR -0.39% Intraday chart for Sanofi +0.11% +2.03%

Financials

Sales 2024 * 46.24B 49.76B 68.1B Sales 2025 * 49.92B 53.72B 73.52B Capitalization 114B 123B 168B
Net income 2024 * 7.13B 7.67B 10.5B Net income 2025 * 8.66B 9.32B 12.75B EV / Sales 2024 * 2.61 x
Net Debt 2024 * 6.56B 7.06B 9.66B Net Debt 2025 * 1.95B 2.1B 2.87B EV / Sales 2025 * 2.32 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
13.2 x
Employees 86,088
Yield 2024 *
4.21%
Yield 2025 *
4.46%
Free-Float 87.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.39%
1 week+0.11%
Current month-1.65%
1 month+3.18%
3 months+4.09%
6 months+7.13%
Current year+2.03%
More quotes
1 week
91.29
Extreme 91.29
93.32
1 month
85.02
Extreme 85.02
93.32
Current year
85.00
Extreme 85
96.30
1 year
80.80
Extreme 80.8
104.30
3 years
76.52
Extreme 76.52
106.46
5 years
67.79
Extreme 67.79
106.46
10 years
62.88
Extreme 62.88
106.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-05-03 91.56 -0.39% 1,908
24-05-02 91.92 -1.27% 3,556
24-04-30 93.1 +1.78% 1,063
24-04-29 91.47 +0.01% 1,863
24-04-26 91.46 -0.48% 2,928

Delayed Quote Xetra, May 03, 2024 at 11:35 am

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
91.3 EUR
Average target price
108.1 EUR
Spread / Average Target
+18.36%
Consensus